经门静脉化疗栓塞或化疗治疗肝细胞癌──附63例报道

６３例不能手术切除的肝细胞癌伴肝硬化病人．接受肝动脉和门静脉分期化疗栓塞（６０例）或同时化疗栓塞（３例）．其中６例辅以门静脉插管化疗。１、２、３ａ生存率分别７１．４％（４５／６３）、３１．７％（２０／６３）和３．２％（２／６３）。临床研究证明．肝动脉和门静脉化疗栓塞的姑息性治疗效果优于单纯肝动脉化疗栓塞。门静脉插管途径可以选择口肠静脉或中结肠静脉．当有栓塞禁忌症或经肝动脉化疗已无可能时．经门静脉系统灌注化疗药物，其在肝内肿瘤中的浓度与肝动脉灌注药物相似。

Chemoembolization or infusion of cytostatics via the portal vein for hepatocellular carcinoma: A report of 63 cases

From September 1988 to September 1993, 63 patients who suffered from hepatocellular carcinoma with cirrhosis were carriedout surgical exploration.of them,60 patientsunderwent hepatic arterial or.portal.venouschemoembolization sequentially and 3 patientssimultaneously both procedures owing to inoperable diseases.Six of them who had intrahepaticspreading tumors more than one lobe at the timeof second laparotomy without employing intraarterial way were Performed the infusion of cytostatics via the portal vein.Overall survival ratesof this 63 Patients were 71.4 Percent at 1 year(45of 63),31.7percent at 2 years(20 of 63),3.2 Percent at 3 years(2of 63)respectively after treatment.Hepatic arterial combined portalvenous embolization can contribute much betterpalliative effects for hepatocellular carcinoma ascompared with hepatic artery embolization only.The way with portal embolization may be differrent.The way which we used successfully via thelieal vein or midiocolonic vein. When there werecontraindications for embolization or no way forhepatic artery infusion, portal vein infusioncould also supply as much cytostatics concentration in tumors as arterial infusion.